KR101754940B1 - 3-치환된 1ｈ-피롤 및 방향족 및 헤테로 방향족 스페이서에 동시에 기반한 신규한 히스톤 디아세틸라아제 저해제 - Google Patents
3-치환된 1ｈ-피롤 및 방향족 및 헤테로 방향족 스페이서에 동시에 기반한 신규한 히스톤 디아세틸라아제 저해제 Download PDFInfo
- Publication number
- KR101754940B1 KR101754940B1 KR1020127011407A KR20127011407A KR101754940B1 KR 101754940 B1 KR101754940 B1 KR 101754940B1 KR 1020127011407 A KR1020127011407 A KR 1020127011407A KR 20127011407 A KR20127011407 A KR 20127011407A KR 101754940 B1 KR101754940 B1 KR 101754940B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- carbonyl
- formula
- pyrrole
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *=C(c1ccc(CNC(c([n]c(-c2c[o]cc2)c2)c2-c(cc2)ccc2F)=O)cc1)NO Chemical compound *=C(c1ccc(CNC(c([n]c(-c2c[o]cc2)c2)c2-c(cc2)ccc2F)=O)cc1)NO 0.000 description 3
- CVIKZWAGJKKZKA-UHFFFAOYSA-M COc(cc1)ccc1-c1c(C(NCc(cc2)ccc2C(NCCS)=O)=O)[n-]c(-c2ccccc2)c1 Chemical compound COc(cc1)ccc1-c1c(C(NCc(cc2)ccc2C(NCCS)=O)=O)[n-]c(-c2ccccc2)c1 CVIKZWAGJKKZKA-UHFFFAOYSA-M 0.000 description 1
- VWPYPJQYNJIVCP-UHFFFAOYSA-N COc(cc1)ccc1-c1cc(-c2c[o]cc2)c(C(NCc(cc2)ccc2C(NO)=O)=O)[nH]1 Chemical compound COc(cc1)ccc1-c1cc(-c2c[o]cc2)c(C(NCc(cc2)ccc2C(NO)=O)=O)[nH]1 VWPYPJQYNJIVCP-UHFFFAOYSA-N 0.000 description 1
- AKCXYHNDQWTRCG-UHFFFAOYSA-N ONC(c1ccc(CNC(c([nH]c(-c2ccccc2)c2)c2-c(cc2Cl)ccc2Cl)=O)cc1)=O Chemical compound ONC(c1ccc(CNC(c([nH]c(-c2ccccc2)c2)c2-c(cc2Cl)ccc2Cl)=O)cc1)=O AKCXYHNDQWTRCG-UHFFFAOYSA-N 0.000 description 1
- CWLLRSZGVIEFEZ-UHFFFAOYSA-N ONC(c1ccc(CNC(c([nH]c(-c2ccccc2)c2)c2-c(cc2F)ccc2F)=O)cc1)=O Chemical compound ONC(c1ccc(CNC(c([nH]c(-c2ccccc2)c2)c2-c(cc2F)ccc2F)=O)cc1)=O CWLLRSZGVIEFEZ-UHFFFAOYSA-N 0.000 description 1
- IQKQZJZTRCSTJI-UHFFFAOYSA-N ONC(c1ccc(CNC(c([nH]c(-c2ccccc2)c2)c2-c2cccc(Br)c2)=O)cc1)=O Chemical compound ONC(c1ccc(CNC(c([nH]c(-c2ccccc2)c2)c2-c2cccc(Br)c2)=O)cc1)=O IQKQZJZTRCSTJI-UHFFFAOYSA-N 0.000 description 1
- OUFJXJJAONPLLU-UHFFFAOYSA-N Oc(cc1)ccc1-c1cc(-c2c[o]cc2)c(C(NCc(cc2)ccc2C(NO)=O)=O)[nH]1 Chemical compound Oc(cc1)ccc1-c1cc(-c2c[o]cc2)c(C(NCc(cc2)ccc2C(NO)=O)=O)[nH]1 OUFJXJJAONPLLU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382193.2 | 2009-10-02 | ||
| EP09382193A EP2305643A1 (en) | 2009-10-02 | 2009-10-02 | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
| PCT/EP2010/064653 WO2011039353A1 (en) | 2009-10-02 | 2010-10-01 | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120091176A KR20120091176A (ko) | 2012-08-17 |
| KR101754940B1 true KR101754940B1 (ko) | 2017-07-06 |
Family
ID=41716282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127011407A Active KR101754940B1 (ko) | 2009-10-02 | 2010-10-01 | 3-치환된 1ｈ-피롤 및 방향족 및 헤테로 방향족 스페이서에 동시에 기반한 신규한 히스톤 디아세틸라아제 저해제 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8685992B2 (enExample) |
| EP (2) | EP2305643A1 (enExample) |
| JP (1) | JP5746185B2 (enExample) |
| KR (1) | KR101754940B1 (enExample) |
| CN (1) | CN102648177B (enExample) |
| AU (1) | AU2010302572B2 (enExample) |
| BR (1) | BR112012007411B8 (enExample) |
| CA (1) | CA2776351C (enExample) |
| ES (1) | ES2452868T3 (enExample) |
| IL (1) | IL218995A (enExample) |
| IN (1) | IN2012DN03129A (enExample) |
| MX (1) | MX2012003988A (enExample) |
| PL (1) | PL2483242T3 (enExample) |
| PT (1) | PT2483242E (enExample) |
| RU (1) | RU2549885C2 (enExample) |
| WO (1) | WO2011039353A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013008898A2 (pt) * | 2010-10-11 | 2016-06-28 | Auckland Uniservices Limited | benzamidas substituídas e seus usos |
| CA2908542C (en) * | 2013-04-29 | 2017-08-01 | Chong Kun Dang Pharmaceutical Corp. | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| TW201629026A (zh) | 2015-02-02 | 2016-08-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸 |
| WO2017029684A1 (en) * | 2015-08-17 | 2017-02-23 | University Of Mysore | 2,3,5 trisubstituted pyrrole derivatives as topoisomerase inhibitors and therapeutic uses thereof |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| CN107793375A (zh) * | 2016-08-31 | 2018-03-13 | 中国科学院上海药物研究所 | 一类芳基2,2’‑串联双噻唑类化合物及其制备方法和用途 |
| EP3318256A1 (en) * | 2016-11-08 | 2018-05-09 | Quimatryx, S.L | Compounds for the treatment of autoimmune diseases |
| GB201708457D0 (en) * | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Inhibitors of metallo-beta-lactamases |
| CN110938055A (zh) * | 2018-09-21 | 2020-03-31 | 华东师范大学 | 六元环甲酰胺类化合物及其合成方法和应用 |
| AU2020259100B2 (en) | 2019-04-17 | 2024-12-12 | Fundación Kertor | 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors |
| CN112516142B (zh) * | 2020-12-11 | 2021-10-15 | 北京华氏精恒医药科技有限公司 | 一种具有hdac抑制活性的药物组合物、制备方法及其用途 |
| CN112225737B (zh) * | 2020-12-11 | 2021-04-09 | 北京鑫开元医药科技有限公司 | 具有hdac抑制活性的化合物、制备方法、组合物及用途 |
| CN116813560A (zh) * | 2022-03-28 | 2023-09-29 | 上海科技大学 | 三唑酰胺类化合物及其制备方法和用途 |
| CN114558004B (zh) * | 2022-03-29 | 2023-08-11 | 奎马特里克斯有限公司 | Qtx125药物制剂 |
| CN114634489B (zh) * | 2022-04-19 | 2023-07-04 | 奎马特里克斯有限公司 | 结晶形式 |
| CN114652715B (zh) * | 2022-04-29 | 2023-04-25 | 奎马特里克斯有限公司 | 联合疗法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108864A2 (en) | 2005-04-15 | 2006-10-19 | Dominion Pharmakine S.L. | New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof |
| WO2007074176A1 (es) | 2005-12-27 | 2007-07-05 | Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea (Upv-Ehu) | Nuevos derivados pirrólicos con actividad inhibidora de desacetilasas de histonas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| CA2547573A1 (en) * | 2003-12-05 | 2005-06-23 | Warner-Lambert Company Llc | N-alkyl pyrroles as hmg-coa reductase inhibitors |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| BRPI0817897A2 (pt) * | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
-
2009
- 2009-10-02 EP EP09382193A patent/EP2305643A1/en not_active Withdrawn
-
2010
- 2010-10-01 MX MX2012003988A patent/MX2012003988A/es active IP Right Grant
- 2010-10-01 ES ES10763676.3T patent/ES2452868T3/es active Active
- 2010-10-01 WO PCT/EP2010/064653 patent/WO2011039353A1/en not_active Ceased
- 2010-10-01 US US13/499,839 patent/US8685992B2/en active Active
- 2010-10-01 EP EP10763676.3A patent/EP2483242B1/en active Active
- 2010-10-01 CA CA2776351A patent/CA2776351C/en active Active
- 2010-10-01 PL PL10763676T patent/PL2483242T3/pl unknown
- 2010-10-01 KR KR1020127011407A patent/KR101754940B1/ko active Active
- 2010-10-01 PT PT107636763T patent/PT2483242E/pt unknown
- 2010-10-01 RU RU2012117885/04A patent/RU2549885C2/ru not_active IP Right Cessation
- 2010-10-01 BR BR112012007411A patent/BR112012007411B8/pt active IP Right Grant
- 2010-10-01 IN IN3129DEN2012 patent/IN2012DN03129A/en unknown
- 2010-10-01 AU AU2010302572A patent/AU2010302572B2/en active Active
- 2010-10-01 CN CN201080052814.XA patent/CN102648177B/zh active Active
- 2010-10-01 JP JP2012531445A patent/JP5746185B2/ja active Active
-
2012
- 2012-04-02 IL IL218995A patent/IL218995A/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108864A2 (en) | 2005-04-15 | 2006-10-19 | Dominion Pharmakine S.L. | New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof |
| WO2007074176A1 (es) | 2005-12-27 | 2007-07-05 | Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea (Upv-Ehu) | Nuevos derivados pirrólicos con actividad inhibidora de desacetilasas de histonas |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102648177A (zh) | 2012-08-22 |
| AU2010302572A8 (en) | 2012-05-24 |
| RU2012117885A (ru) | 2013-11-10 |
| IN2012DN03129A (enExample) | 2015-09-18 |
| ES2452868T3 (es) | 2014-04-03 |
| IL218995A (en) | 2016-11-30 |
| PL2483242T3 (pl) | 2014-05-30 |
| EP2305643A1 (en) | 2011-04-06 |
| CA2776351A1 (en) | 2011-04-07 |
| IL218995A0 (en) | 2012-06-28 |
| AU2010302572B2 (en) | 2016-10-20 |
| JP5746185B2 (ja) | 2015-07-08 |
| PT2483242E (pt) | 2014-03-17 |
| CA2776351C (en) | 2017-10-31 |
| US8685992B2 (en) | 2014-04-01 |
| BR112012007411A2 (pt) | 2016-12-06 |
| JP2013506637A (ja) | 2013-02-28 |
| HK1173450A1 (en) | 2013-05-16 |
| RU2549885C2 (ru) | 2015-05-10 |
| CN102648177B (zh) | 2015-01-07 |
| BR112012007411B8 (pt) | 2021-05-25 |
| WO2011039353A1 (en) | 2011-04-07 |
| US20120196885A1 (en) | 2012-08-02 |
| MX2012003988A (es) | 2012-07-23 |
| EP2483242A1 (en) | 2012-08-08 |
| KR20120091176A (ko) | 2012-08-17 |
| EP2483242B1 (en) | 2013-12-11 |
| AU2010302572A1 (en) | 2012-05-17 |
| BR112012007411B1 (pt) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2483242B1 (en) | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers | |
| DE69809758T2 (de) | Indol verbindungen als cox-2 inhibitoren | |
| RU2634694C2 (ru) | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения | |
| KR100894189B1 (ko) | 5-ｈｔ6 수용체의 길항제로서의 ｎ-(2-아릴에틸)벤질아민 | |
| KR101559597B1 (ko) | ５―원 헤테로시클릭 화합물 | |
| CA2415899A1 (en) | Medicine comprising dicyanopyridine derivative | |
| PT1024138E (pt) | Derivados de pirazole | |
| MX2014015350A (es) | Compuestos de triazolona como inhibidores de mpegs-1. | |
| JP2008509982A (ja) | アリール尿素誘導体 | |
| US20150038545A1 (en) | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof | |
| JP2008525434A (ja) | 新規な化合物 | |
| CN101389610B (zh) | 作为香草素受体1(vr1)抑制剂的新苯并咪唑衍生物 | |
| WO2015004610A1 (en) | 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction | |
| KR20080105092A (ko) | 피롤 유도체 또는 그의 염 | |
| JP2003252854A (ja) | アンドロゲン受容体拮抗剤 | |
| JP2010514824A (ja) | 置換ｎ−（４−シアノ−１ｈ−ピラゾール−３−イル）メチルアミン誘導体、これらの調製およびこれらの治療的使用 | |
| HK1173450B (en) | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers | |
| AU2023322448A1 (en) | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors | |
| MXPA00000890A (en) | Indole compounds as cox-2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20200617 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20210621 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20220615 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 9 |